The goals of the proposed study are to test whether it is possible 1) to maximize the benefits and reduce the risks of maintenance drug treatment for schizophrenia by using reduced dose strategies; 2) to employ a family management intervention to further reduce the risk of relapse, and improve social and intrafamilial functioning. The proposed study will be part of a collaborative project sponsored by the National Institute of Mental Health. One hundred ten patients will enter the study over a 2 1/2 year period, each treated for two years. Patients will be randomly assigned to one of the following antipsychotic drug treatments: Continuous low dose (fluphenazine decanoate (FD) 2.5 to 10 mg. every 3 weeks); continuous standard dose (FD 12.5 to 50 mg. every 3 weeks); discrete targeted early intervention (placebo FD 1/2 to 2 cc q 3 weeks). Each patient will also be randomly assigned to either an applied or supportive family management condition. For patients in all groups, episodes of symptom exacerbation will be treated openly with either haloperidol or FD, in addition to the """"""""blind"""""""" study medication, without breaking the blind. Once the episode is resolved, patients will continue on study treatment only. Patients assigned to applied family management will receive individual family sessions according to a predetermined schedule for the first year. Families of all patients will attend a general education workshop and have the opportunity to attend monthly group meetings throughout the two year period. Outcome measures will include relapse rates, measures of psychopathology, social functioning and side effects.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Long Island Jewish Medical Center
New Hyde Park
United States
Zip Code
Smerud, Phyllis E; Rosenfarb, Irwin S (2008) The therapeutic alliance and family psychoeducation in the treatment of schizophrenia: an exploratory prospective change process study. J Consult Clin Psychol 76:505-10
Rosenfarb, Irwin S; Bellack, Alan S; Aziz, Nahid (2006) Family interactions and the course of schizophrenia in African American and White patients. J Abnorm Psychol 115:112-20
Blanchard, Jack J; Horan, William P; Collins, Lindsay M (2005) Examining the latent structure of negative symptoms: is there a distinct subtype of negative symptom schizophrenia? Schizophr Res 77:151-65
Rosenfarb, Irwin S; Bellack, Alan S; Aziz, Nahid et al. (2004) Race, family interactions, and patient stabilization in schizophrenia. J Abnorm Psychol 113:109-15
Wuerker, A K; Haas, G L; Bellack, A S (2001) Interpersonal control and expressed emotion in families of persons with schizophrenia: change over time. Schizophr Bull 27:671-85
Salyers, M P; Mueser, K T (2001) Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr Res 48:109-23
Mueser, K T; Salyers, M P; Mueser, P R (2001) A prospective analysis of work in schizophrenia. Schizophr Bull 27:281-96
Mueser, K T; Sengupta, A; Schooler, N R et al. (2001) Family treatment and medication dosage reduction in schizophrenia: effects on patient social functioning, family attitudes, and burden. J Consult Clin Psychol 69:3-12
Bellack, A S; Haas, G L; Schooler, N R et al. (2000) Effects of behavioural family management on family communication and patient outcomes in schizophrenia. Br J Psychiatry 177:434-9
Schulz, S C; Thompson, P A; Jacobs, M et al. (1999) Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. J Clin Psychiatry 60:366-72

Showing the most recent 10 out of 21 publications